Vaxcyte
PCVX
66.96
+0.26
+0.39%
Vaxcyte
US · PCVX
#1630 by market cap
Listed 2020
66.96
+0.26
+0.39%
Live - 5344 symbols - heartbeat 331s ago
· 2026-10-08 07:36
Pre-market
66.78
-0.27%
After-hours
66.60
-0.54%
Overnight
66.59
-0.55%
- Market cap
- 9.96B
- P/E (TTM)i
- -8.78
- P/Bi
- 3.61
- EPSi
- -5.63
- Div yieldi
- 0.00%
- 52W posi
- 53%
Reader sentiment
Are you bullish or bearish on PCVX?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions decreased by 6 in the most recent period (2026/Q3).
- Total institutional ownership fell 3.4 percentage points.
Institutional ownership
- Held by institutions
- 113.30% -3.35pp
- Institutions
- 400 -6
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund84.47%
Hedge Fund12.65%
VC/PE Fund12.22%
Public Company1.81%
Sovereign Wealth Fund0.84%
Individual/Insider0.60%
Government Pension Fund0.56%
Private Company0.52%
Insurance Company0.20%
Top holders as of 2026-06-30
FMR
12.87% · 19.15M sh
Janus Henderson Group plc
12.12% · 18.04M sh
T. Rowe Price Group, Inc.
10.21% · 15.20M sh
BlackRock
8.11% · 12.07M sh
RA Capital Management, L.P.
7.71% · 11.47M sh
Vanguard Capital Management, LLC
4.89% · 7.28M sh
Wellington Management Group
4.71% · 7.00M sh
Vanguard Portfolio Management, LLC
4.43% · 6.59M sh
State Street Global Advisors
3.60% · 5.35M sh
Deep Track Capital, LP
2.89% · 4.30M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 19 buys · 30 sells
| Name | Role | Stake |
|---|---|---|
| Grant Pickering | Chief Executive Officer | 0.39% |
| Andrew Guggenhime | President | 0.07% |
| James Wassil | Chief Operating Officer | 0.07% |
| Harpreet Dhaliwal | -- | 0.01% |
| Heath Lukatch | Independent Director | 0.01% |
| Elvia Cowan | Senior VP of Finance & Principal Accounting Officer | 0.01% |
| Halley Gilbert | Independent Director | 0.01% |
| Teri Loxam | Independent Director | 0.01% |
| Annie Drapeau | Independent Director | 0.01% |
| Carlos Paya | Independent Chairperson | 0.01% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-10-04 | James Wassil | Chief Operating Officer | Intent to Sell (Form 144) | -18,000 | $86.74 |
| 2026-10-04 | Elvia Cowan | Senior VP of Finance & Principal Accounting Officer | Intent to Sell (Form 144) | -19,000 | $86.74 |
| 2026-09-30 | James Wassil | Chief Operating Officer | Derivative Exercise and Sale | -2,250 | $5.35–57.09 |
| 2026-09-08 | James Wassil | Chief Operating Officer | Automatic Disposition | -2,715 | $59.52–61.16 |
| 2026-09-08 | James Wassil | Chief Operating Officer | Intent to Sell (Form 144) | -1,334 | $59.99 |
| 2026-09-07 | Andrew Guggenhime | President | Sale to Issuer | -7,155 | $60.36 |
| 2026-09-07 | Grant Pickering | Chief Executive Officer | Sale to Issuer | -17,056 | $60.36 |
| 2026-09-07 | James Wassil | Chief Operating Officer | Sale to Issuer | -5,459 | $60.36 |
| 2026-09-07 | Elvia Cowan | Senior VP of Finance & Principal Accounting Officer | Sale to Issuer | -1,327 | $60.36 |
| 2026-09-07 | Harpreet Dhaliwal | -- | Sale to Issuer | -7,651 | $60.36 |
| 2026-09-03 | James Wassil | Chief Operating Officer | Intent to Sell (Form 144) | -1,381 | $59.73 |
| 2026-09-03 | Luis Jodar | Chief Medical Officer | Other Acquisition | +52,632 | -- |
| 2026-09-03 | Luis Jodar | Chief Medical Officer | Other Derivative Acquisition | +88,254 | $61.16 |
| 2026-09-01 | Andrew Guggenhime | President | Sale to Issuer | -2,705 | $60.74–61.58 |
| 2026-09-01 | Grant Pickering | Chief Executive Officer | Sale to Issuer | -6,289 | $60.74–61.58 |
| 2026-09-01 | James Wassil | Chief Operating Officer | Sale to Issuer | -2,705 | $60.74–61.58 |
| 2026-09-01 | Elvia Cowan | Senior VP of Finance & Principal Accounting Officer | Sale to Issuer | -569 | $60.74–61.58 |
| 2026-09-01 | Harpreet Dhaliwal | -- | Sale to Issuer | -1,020 | $60.74–61.58 |
| 2026-08-31 | James Wassil | Chief Operating Officer | Automatic Disposition | -1,227 | $60.96–61.42 |
| 2026-08-31 | James Wassil | Chief Operating Officer | Derivative Exercise and Sale | -2,250 | $5.35–61.48 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 07:36:37 · For reference only, not investment advice and not tailored to your situation.